Pituitary Tumor
44
7
9
10
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
4 terminated out of 44 trials
71.4%
-15.1% vs benchmark
5%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (44)
Perimetry Based on Eye-movements in Patients With (Supra)Sellar Tumors
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Long-Term Longitudinal QoL in Patients Undergoing EEA
NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm
Pituitary Tumor Surveillance: Pathogenic Correlation
Evaluation of the CONVIVO System
The PROMISE Survey
Validation of a Quality of Life Metric "Prolac-10"
Nasal Packing Following Endoscopic Endonasal Pituitary Resection
Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions
Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Using Polyglycolic Acid Mesh Prevents Cerebrospinal Fluid Leakage
Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery
To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
Electrophysiology of the Human Pituitary Gland
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery